NIH data: " Median survival after biopsy alone for GBM patients is frequently reported to be lower (4–5 months) compared to those who undergo surgical resection (up to 11–14 months in large clinical studies)." So ECA trials that had screeners allowing biopsy only patients who would have shorter life expectancy that DCVax-L's screen requiring total resection. It's is a biased comparison.
Market Data 
Markets 
AI
